PERsistent Sitagliptin treatment & Outcomes (PERS&O 2.0) study, long-term results: a real-world observation on DPP4-inhibitor effectiveness

INTRODUCTION: Sitagliptin is a dipeptidyl peptidase 4 inhibitor for the treatment of type 2 diabetes (T2D). Limited real-world data on its effectiveness and safety are available from an Italian population. RESEARCH DESIGN AND METHODS: We evaluated long-term clinical data from the single-arm PERsiste...

Descripción completa

Detalles Bibliográficos
Autores principales: Bossi, Antonio Carlo, De Mori, Valentina, Galeone, Carlotta, Bertola, Davide Pietro, Gaiti, Margherita, Balini, Annalisa, Berzi, Denise, Forloni, Franco, Meregalli, Giancarla, Turati, Federica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Cardiovascular and Metabolic Risk
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478001/
https://www.ncbi.nlm.nih.gov/pubmed/32900698
http://dx.doi.org/10.1136/bmjdrc-2020-001507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478001/
https://www.ncbi.nlm.nih.gov/pubmed/32900698
http://dx.doi.org/10.1136/bmjdrc-2020-001507

Ejemplares similares